Yooyoung Pharmaceutical

Focus: Yooyoung Pharmaceutical is a Korean generics and orthobiologics company founded in 2021, headquartered in Jincheon with a focused pipeline across metabolic, cardiovascular, and oncology indications.

Metabolic Diseases Cardiovascular Oncology

Profile data last refreshed 5h ago · AI intelligence enriched 2w ago

Open Jobs

About Yooyoung Pharmaceutical

AI assessmentNot Hiring

No open roles listed right now. Follow Yooyoung Pharmaceutical to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

9 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

HyaleXo

Knee Osteoarthritis

N/A

Clinical Trials (1)

NCT07096050Post Marketing Clinical Follow up Study of HyaleXo

N/A

Help build intelligence for Yooyoung Pharmaceutical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Active clinical pipeline with 9 Phase 3 programs providing near-term catalysts and visibility
Diversified therapeutic focus (metabolic, cardiovascular, oncology, orthobiologics) offers exposure across multiple growth areas
Growing commercial organization (6 sales/marketing roles) indicates scaling phase with expansion opportunity

Watch Out For

Newly founded (2021) with limited public financial data, revenue history, or market validation
Only 9 active job openings across entire company suggests constrained hiring and limited career mobility
No disclosed funding, revenue, or cash position raises questions about financial stability and runway

Generated by Claude from Yooyoung Pharmaceutical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

A Observational Study to Evaluate Lipid-lowering Drug Its Effect on Parameters in Dyslipidemia of Ty

Complex Dyslipidemia

N/A

Clinical Trials (1)

NCT02382159A Observational Study to Evaluate Lipid-lowering Drug Its Effect on Parameters in Dyslipidemia of Type 2 Diabetes.

N/A

Post Marketing Clinical Follow up Study to Evaluate the Performance and Safety of ORTHIX PLUS

Osteoarthritis, Knee

N/A

Clinical Trials (1)

NCT05348525Post Marketing Clinical Follow up Study to Evaluate the Performance and Safety of ORTHIX PLUS

N/A

Prospective Observational Study of Pravafenix Cap

Dyslipidemias

N/A

Clinical Trials (1)

NCT03214211Prospective Observational Study of Pravafenix Cap

N/A

Post Marketing Clinical Follow up Study to Evaluate the Performance and Safety of HYALEXO

Osteoarthritis

N/A

Clinical Trials (1)

NCT05229458Post Marketing Clinical Follow up Study to Evaluate the Performance and Safety of HYALEXO

N/A

YYC506-T and YYC506-A

Dyslipidemias

Phase 1

Clinical Trials (1)

NCT04874129Phase 1 to Evaluate the Safety and Pharmacokinetic Characteristics of Fixed-dose Combination of YYC506

Phase 1

YYC506-T

Dyslipidemias

Phase 1

Clinical Trials (1)

NCT04874142Phase 1 to Evaluate the Safety and Pharmacokinetic Durg-drug Interaction of YYC506-T and YYC506-A

Phase 1

YYD601 1

GERD

Phase 1

Clinical Trials (1)

NCT03558477PK/PD Clinical Trial of YYD601 in Healthy Adult Male

Phase 1

YYD601 20mg

GERD

Phase 1

Clinical Trials (1)

NCT03985319Clinical Trial to Assess the PK/PD of YYD601 20mg After Oral Administration if Healthy Adult Subjects (Phase1)

Phase 1

YYD302 2ml

Osteoarthritis, Knee

Phase 1/2

Clinical Trials (1)

NCT02965495Clinical Trial of YYD302 for Treatment of Osteoarthritis of the Knee

Phase 1/2

YY1201 2ml

Osteoarthritis, Knee

Phase 1/2

Clinical Trials (1)

NCT02554552Clinical Trial of YY1201 for Treatment of Osteoarthritis of the Knee

Phase 1/2

YYB101

Colorectal Cancer Metastatic

Phase 1/2

Clinical Trials (1)

NCT04368507To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of YYB101 With Irinotecan, Patients Who Are Metastatic or Recurrent Colorectal Cancer Patients

Phase 1/2

Celecoxib 200mg

Osteoarthritis, Knee

Phase 2

Clinical Trials (1)

NCT03850587Clinical Trial of YYC301 for Treatment of Osteoarthritis of the Knee

Phase 2

YYD601 20mg

Non-erosive Reflux Disease

Phase 3

Clinical Trials (1)

NCT03967886Clinical Trial to Assess the Efficacy and Safety of YYD601 in NERD Patients